Adoptive Transfer of Epstein-Barr Virus (EBV) Nuclear Antigen 1-Specific T Cells As Treatment for EBV Reactivation and Lymphoproliferative Disorders After Allogeneic Stem-Cell Transplantation

被引：217

作者：

Icheva, Vanya ^{[1
]}

Kayser, Simone ^{[1
]}

Wolff, Daniel ^{[4
]}

Tuve, Sebastian ^{[5
]}

Kyzirakos, Christina ^{[2
]}

Bethge, Wolfgang ^{[3
]}

Greil, Johann ^{[6
]}

Albert, Michael H. ^{[7
]}

Schwinger, Wolfgang ^{[9
]}

Nathrath, Michaela ^{[8
]}

Schumm, Michael ^{[1
]}

Stevanovic, Stefan ^{[2
]}

Handgretinger, Rupert ^{[1
]}

Lang, Peter ^{[1
]}

Feuchtinger, Tobias ^{[1
]}

机构：

[1] Univ Childrens Hosp Tubingen, Tubingen, Germany

[2] Univ Tubingen, D-72076 Tubingen, Germany

[3] Univ Tubingen Hosp, Tubingen, Germany

[4] Univ Hosp Regensburg, Regensburg, Germany

[5] Univ Hosp Dresden, Dresden, Germany

[6] Univ Childrens Hosp Heidelberg, Heidelberg, Germany

[7] Haunersches Childrens Hosp Munchen, Munich, Germany

[8] Helmholtz Zentrum Munchen, Munich, Germany

[9] Univ Childrens Hosp Graz, Graz, Austria

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 01期

关键词：

ADENOVIRUS INFECTION; VIRAL-INFECTIONS; DISEASE; RECIPIENTS; IMMUNOTHERAPY; EXPANSION; EFFECTOR; THERAPY; CD4(+); RISK;

D O I：

10.1200/JCO.2011.39.8495

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose Reactivation of Epstein-Barr virus (EBV) after allogeneic stem-cell transplantation (SCT) can lead to severe life-threatening infections and trigger post-transplantation lymphoproliferative disease (PTLD). Since EBV-specific T cells could prevent PTLD, cellular immunotherapy has been a promising treatment option. However, generation of antigen-specific T-cell populations has been difficult within a short time frame. Patients and Methods To improve availability in urgent clinical conditions, we developed a rapid protocol for isolation of polyclonal EBV nuclear antigen 1 (EBNA-1) -specific T cells by using an interferon gamma (IFN-gamma) capture technique. Results We report on the use of adoptive transfer of EBNA-1-specific T cells in 10 pediatric and adult patients with EBV viremia and/or PTLD after SCT. No acute toxicity or graft-versus-host disease (GVHD) of more than grade 2 occurred as a result of adoptive T-cell transfer. In vivo expansion of transferred EBNA-1-specific T cells was observed in eight of 10 patients after a median of 16 days following adoptive transfer that was associated with clinical and virologic response in seven of them (70%). None of the responders had EBV-associated mortality. Within clinical responders, three patients were disease free by the day of last follow-up (2 to 36 months), three patients died of other infectious complications, and one patient died as a result of relapse of malignancy. EBV-related mortality was observed in two of 10 patients, and another patient had ongoing viremia without clinical symptoms at last follow-up. Conclusion Adoptive ex vivo transfer of EBNA-1-specific T cells is a feasible and well-tolerated therapeutic option, representing a fast and efficient procedure to achieve reconstitution of antiviral T-cell immunity after SCT. J Clin Oncol 31:39-48. (c) 2012 by American Society of Clinical Oncology

引用

页码：39 / 48

页数：10

共 39 条

[11] Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation [J].

Feuchtinger, Tobias ;

Opherk, Kathrin ;

Bethge, Wolfgang A. ;

Topp, Max S. ;

Schuster, Friedhelm R. ;

Weissinger, Eva M. ;

Mohty, Mohamad ;

Or, Reuven ;

Maschan, Michael ;

Schumm, Michael ;

Hamprecht, Klaus ;

Handgretinger, Rupert ;

Lang, Peter ;

Einsele, Hermann .

BLOOD, 2010, 116 (20) :4360-4367

[12] Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy [J].

Fujita, Yuriko ;

Leen, Ann M. ;

Sun, Jiali ;

Nakazawa, Yozo ;

Yvon, Eric ;

Heslop, Helen E. ;

Brenner, Malcohn K. ;

Rooney, Cliona M. .

JOURNAL OF IMMUNOTHERAPY, 2008, 31 (07) :665-674

[13]

Gattinoni L, 2005, J CLIN INVEST, V115, P1616, DOI 10.1172/JCI24480

[14] Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease:: prophylactic infusion of EBV-specific cytotoxic T cells [J].

Gustafsson, Å ;

Levitsky, V ;

Zou, JZ ;

Frisan, T ;

Dalianis, T ;

Ljungman, P ;

Ringden, O ;

Winiarski, J ;

Ernberg, I ;

Masucci, MG .

BLOOD, 2000, 95 (03) :807-814

[15]

Handgretinger R, 2001, ANN NY ACAD SCI, V938, P340

[16] EPSTEIN-BARR INFECTION AFTER BONE-MARROW TRANSPLANTATION [J].

HESLOP, HE ;

LI, CF ;

KRANCE, RA ;

LOFTIN, SK ;

ROONEY, CM .

BLOOD, 1994, 83 (06) :1706-1708

[17] Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients [J].

Heslop, Helen E. ;

Slobod, Karen S. ;

Pule, Martin A. ;

Hale, Gregory A. ;

Rousseau, Alexandra ;

Smith, Colton A. ;

Bollard, Catherine M. ;

Liu, Hao ;

Wu, Meng-Fen ;

Rochester, Richard J. ;

Amrolia, Persis J. ;

Hurwitz, Julia L. ;

Brenner, Malcolm K. ;

Rooney, Cliona M. .

BLOOD, 2010, 115 (05) :925-935

[18] How I treat EBV lymphoproliferation [J].

Heslop, Helen E. .

BLOOD, 2009, 114 (19) :4002-4008

[19] Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders [J].

Jones, Kimberley ;

Nourse, Jamie P. ;

Morrison, Leanne ;

Nguyen-Van, Do ;

Moss, Denis J. ;

Burrows, Scott R. ;

Gandhi, Maher K. .

BLOOD, 2010, 116 (13) :2245-2252

[20] Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals [J].

Leen, Ann M. ;

Myers, G. Doug ;

Sili, Uluhan ;

Huls, M. Helen ;

Weiss, Heidi ;

Leung, Kathryn S. ;

Carrum, George ;

Krance, Robert A. ;

Chang, Chung-Che ;

Molldrem, Jeffrey J. ;

Gee, Adrian P. ;

Brenner, Malcolm K. ;

Heslop, Helen E. ;

Rooney, Cliona M. ;

Bollard, Catherine M. .

NATURE MEDICINE, 2006, 12 (10) :1160-1166

← 1 2 3 4 →